BIO REFERENCE LABS's gross profit margin for the first quarter of its fiscal year 2015 has increased when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. BIO REFERENCE LABS has strong liquidity. Currently, the Quick Ratio is 1.97 which shows the ability to cover short-term cash needs. The company managed to increase its liquidity from the same period a year ago, despite already having strong liquidity to begin with. This would indicate improved cash flow.
During the same period, stockholders' equity ("net worth") has increased by 18.49% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY15||Q1 FY14|
|Net Sales ($mil)||208.83||181.27|
|Net Income ($mil)||6.63||2.95|
|Balance Sheet||Q1 FY15||Q1 FY14|
|Cash & Equiv. ($mil)||22.24||14.53|
|Total Assets ($mil)||488.14||427.64|
|Total Debt ($mil)||55.3||52.63|
|Profitability||Q1 FY15||Q1 FY14|
|Gross Profit Margin||45.36||42.33|
|Return on Assets||10.33||9.38|
|Return on Equity||15.48||14.58|
|Debt||Q1 FY15||Q1 FY14|
|Share Data||Q1 FY15||Q1 FY14|
|Shares outstanding (mil)||27.75||27.71|
|Div / share||0.0||0.0|
|Book value / share||11.74||9.92|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||213246.0||238473.0|
BUY. This stock's P/E ratio indicates a discount compared to an average of 25.98 for the Health Care Providers & Services industry and a discount compared to the S&P 500 average of 20.83. To use another comparison, its price-to-book ratio of 2.88 indicates valuation on par with the S&P 500 average of 2.88 and a discount versus the industry average of 3.78. The current price-to-sales ratio is well below the S&P 500 average, but above the industry average. Upon assessment of these and other key valuation criteria, BIO REFERENCE LABS proves to trade at a discount to investment alternatives within the industry.
|BRLI 18.55||Peers 25.98||BRLI 31.87||Peers 14.36|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.
BRLI is trading at a significant discount to its peers.
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
BRLI is trading at a significant premium to its peers.
|BRLI 14.37||Peers 21.30||BRLI 0.97||Peers 1.41|
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.
BRLI is trading at a discount to its peers.
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
BRLI trades at a significant discount to its peers.
|BRLI 2.88||Peers 3.78||BRLI 25.51||Peers 39.99|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
BRLI is trading at a discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, BRLI is expected to significantly trail its peers on the basis of its earnings growth rate.
|BRLI 1.09||Peers 0.88||BRLI 16.92||Peers 13.73|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
BRLI is trading at a premium to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
BRLI has a sales growth rate that exceeds its peers.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV